TBPH Stock Recent News

Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's financials have shown improvement, with increased revenue and reduced R&D costs. Theravance's products, YUPELRI and Ampreloxetine, show promise in treating COPD and MSA, but face challenges in terms of off-target effects and competition from established drugs.

Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation for COPD treatment, but isn't yet a long-term compounder. Collaboration revenues and YUPELRI sales are increasing, but the sentiment remains neutral and valuation is rich.

DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS), taking place August 27-31, 2023, in Copenhagen, Denmark. "The data presented at this meeting continue to support ampreloxetine's potential to deliver a consistent and durable benefit to MSA patients with nOH with a favorable safety and tolerability profile," said Roy Freeman, MBChB, Professor of Neurology, Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center.

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Rick Graham - Head of Research and Development Aziz Sawaf - Chief Financial Officer Conference Call Participants David Risinger - Leerink Douglas Tsao - H.C. Wainwright Eva Xia Privitera - Cowen Operator Ladies and gentlemen, good afternoon.

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.04 per share a year ago.

DUBLIN , July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market close on Monday, August 7, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initiate a large capital return and launch a strategic review.

DUBLIN , April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.